R P Yeatts1, R B Neves. 1. Department of Ophthalmology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Abstract
PURPOSE: The usefulness of a single intraoperative application of mitomycin C was investigated in repeat dacryocystorhinostomy for membranous failure. METHODS: Mitomycin C (0.3 mg/ml for 3 minutes) was topically applied to the fistula site in eight patients undergoing repeat dacryocystorhinostomy for membranous failure. RESULTS: All patients remain asymptomatic and anatomic patency confirmed by probe and irrigation with a mean follow-up period of 14.6 months (range, 6-26 months). No postoperative complications associated with the use of mitomycin C were observed. CONCLUSIONS: In patients who do not maintain a patent fistula after dacryocystorhinostomy because of membranous occlusion of the rhinostomy site, the adjunctive use of mitomycin C may increase the success rate of repeat dacryocystorhinostomy.
PURPOSE: The usefulness of a single intraoperative application of mitomycin C was investigated in repeat dacryocystorhinostomy for membranous failure. METHODS:Mitomycin C (0.3 mg/ml for 3 minutes) was topically applied to the fistula site in eight patients undergoing repeat dacryocystorhinostomy for membranous failure. RESULTS: All patients remain asymptomatic and anatomic patency confirmed by probe and irrigation with a mean follow-up period of 14.6 months (range, 6-26 months). No postoperative complications associated with the use of mitomycin C were observed. CONCLUSIONS: In patients who do not maintain a patent fistula after dacryocystorhinostomy because of membranous occlusion of the rhinostomy site, the adjunctive use of mitomycin C may increase the success rate of repeat dacryocystorhinostomy.